Furthermore, since MEK inhibition sensitizes MLL-rearranged ALL cells to prednisolone regardless of the RAS mutations status, RAS-wildtype MLL-rearranged infant ALL patients may also benefit from MEK inhibitor treatment through enhanced sensitivity to prednisolone. Here, KMT2A is linked to acute lymphoblastic leukemia.